Female Health (NASDAQ:VERU) Director Harry Fisch purchased 10,000 shares of the firm’s stock in a transaction on Wednesday, March 14th. The stock was acquired at an average price of $1.87 per share, with a total value of $18,700.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Harry Fisch also recently made the following trade(s):
- On Friday, March 16th, Harry Fisch purchased 5,000 shares of Female Health stock. The stock was acquired at an average price of $1.96 per share, with a total value of $9,800.00.
- On Monday, March 12th, Harry Fisch purchased 10,000 shares of Female Health stock. The stock was acquired at an average price of $1.80 per share, with a total value of $18,000.00.
- On Friday, March 9th, Harry Fisch purchased 10,000 shares of Female Health stock. The stock was acquired at an average price of $1.88 per share, with a total value of $18,800.00.
- On Wednesday, March 7th, Harry Fisch purchased 24,000 shares of Female Health stock. The stock was acquired at an average price of $1.62 per share, with a total value of $38,880.00.
NASDAQ:VERU opened at $1.82 on Friday. Female Health has a 52 week low of $0.90 and a 52 week high of $3.00. The firm has a market capitalization of $94.72, a PE ratio of -7.28 and a beta of 0.69.
Female Health (NASDAQ:VERU) last posted its quarterly earnings data on Wednesday, February 14th. The company reported ($0.03) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.03). Female Health had a negative net margin of 73.11% and a negative return on equity of 17.63%. The company had revenue of $2.59 million for the quarter, compared to analyst estimates of $5.30 million. sell-side analysts anticipate that Female Health will post -0.14 earnings per share for the current year.
VERU has been the subject of several recent research reports. Zacks Investment Research cut shares of Female Health from a “hold” rating to a “strong sell” rating in a research report on Saturday, January 6th. HC Wainwright set a $5.00 price target on shares of Female Health and gave the company a “buy” rating in a research report on Tuesday, March 6th. Finally, ValuEngine upgraded shares of Female Health from a “sell” rating to a “hold” rating in a research report on Thursday, March 1st.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/07/veru-inc-veru-director-harry-fisch-acquires-10000-shares-of-stock.html.
About Female Health
Veru Inc operates as a urology and oncology biopharmaceutical company. The company operates through two segments, Commercial; and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.
Receive News & Ratings for Female Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Female Health and related companies with MarketBeat.com's FREE daily email newsletter.